SORIN-GROUP

Sorin Group (MIL:SRN) (Reuters Code: SORIN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, is proud to announce the delivery of its 10,000^th heart-lung machine to Brigham and Women’s Hospital*, Boston, MA, USA.

The heart-lung machine helps sustain a patient undergoing open-heart surgery procedures, providing blood oxygenation and circulation (extracorporeal support) to the brain and major organs while the patient's heart and lungs are temporarily bypassed. Every year, more than 1.5 million patients worldwide suffer from cardiac disease requiring extracorporeal support from a heart-lung machine.

“This is an exciting milestone for Sorin Group that reflects the tremendous trust and collaborative relationship we have established with our customers worldwide,” said Michel Darnaud, President, Cardiac Surgery Business Unit, Sorin Group. “Instilling greater clinical confidence by delivering high performance, reliability and value to our customers and patients is at the core of everything we do.”

Sorin Group has demonstrated a history of breakthroughs in the evolution of extracorporeal perfusion system design and manufacturing dating back to 1973. Today, Sorin manufactures the world’s best-selling heart-lung machine, Sorin S5™.

The S5 heart-lung machine delivers reliability, quality and functionality along with extremely advanced safety features embedded in the equipment. Its modular design permits the quick and easy exchange of individual components with a wide variety of configuration options to accommodate every type of procedure in the most challenging environments. The innovative S5 design also enables better integration with the perfusion circuit, and upgrades can be implemented at any time to ensure hospitals are delivering state-of-the-art technology for optimized patient outcomes.

The S5 heart-lung machine, in particular, represents the foundation of a unique interconnected perfusion system, Sorin HeartLink™, that through the integration with the other perfusion devices, allows the full implementation of the innovative concept of Goal-Directed Perfusion, and the monitoring of critical patient parameters for patient outcomes and daily practice improvement.

“We have long enjoyed a collaborative partnership with Sorin Group and have had great success with Sorin cardiopulmonary equipment and devices,” said Dan Fitzgerald, Chief Perfusionist at Brigham and Women's Hospital. “We are happy to have the opportunity to be working with a highly reliable and patient-focused heart-lung machine.”

Sorin Group innovations continue to help advance cardiopulmonary bypass procedures throughout the world, making them among the safest and most effective heart procedures performed. Sorin offers heart-lung machine equipment, accessories, data management systems and disposable perfusion circuits. The company also manufactures blood management systems, cannulae and other advanced cardiopulmonary products designed to enhance the exceptional results achieved by surgical teams. With its comprehensive portfolio and focus on innovation, Sorin Group is the global market leader in cardiopulmonary solutions. The company’s systems and devices are found in the vast majority of the world’s leading cardiac hospitals.

*Brigham and Women’s Hospital is a major teaching affiliate of Harvard Medical School and—along with Massachusetts General Hospital—is a founding member of the PARTNERS ^® HEALTCARE System in the US. PARTNERS strives to be on the cutting edge of technology in order to provide the best care to their patients. For further information, visit www.partners.org

About Sorin Group
Sorin Group (www.sorin.com ) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, Sorin Group focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement prostheses) and Cardiac Rhythm Management (pacemakers, defibrillators and noninvasive monitoring to diagnose arrhythmias and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment). Every year, over one million patients are treated with Sorin Group devices in more than 100 countries.

For more information, please visit www.sorin.com .

Contact:

Gabriele Mazzoletti, Tel: +39 02 69969785
Mobile: +39 348 9792201
Director, Corporate Communications
Sorin Group
e-mail: corporate.communications@sorin.com
or
Francesca Rambaudi, Tel: +39 02 69969716
Director, Investor Relations
Sorin Group
e-mail: investor.relations@sorin.com

Link:

ClickThru